search
Back to results

TMS Electrochemotherapy for Glioblastoma Multiforme

Primary Purpose

Glioblastoma

Status
Withdrawn
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
TMS
Sponsored by
University of Aarhus
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Glioblastoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Newly diagnosed and histologically confirmed glioblastoma multiform
  • MGMT gene methylation
  • If age < 70, eligibility to comply with the Stupp radio chemotherapy regimen
  • If age > 70, eligibility for stand alone chemotherapeutic treatment
  • Ability to comply with the proposed TMS treatment
  • Use of validated anti-conception for fertile female participants in concordance with guidelines provided by the Danish Health and Medicines Authority

Exclusion Criteria:

  • Pregnancy or nursing
  • Other conditions that may contraindicate the use of transcranial magnetic stimulation
  • Implanted pacemaker or metal contraindicating MRI-scan

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    TMS electrochemotherapy

    Arm Description

    Combined TMS (transcranial magnetic stimulation) and Temozolomide chemotherapy.

    Outcomes

    Primary Outcome Measures

    Time to death
    Time from onset primary diagnosis until death

    Secondary Outcome Measures

    Time to progression
    Time from diagnosis until radiological tumor progression
    Quality of Life

    Full Information

    First Posted
    November 3, 2014
    Last Updated
    September 13, 2021
    Sponsor
    University of Aarhus
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02283944
    Brief Title
    TMS Electrochemotherapy for Glioblastoma Multiforme
    Official Title
    TMS Electrochemotherapy for Glioblastoma Multiforme
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    October 2014
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    Device for multi coil TMS no longer supported
    Study Start Date
    January 2015 (undefined)
    Primary Completion Date
    January 2018 (Anticipated)
    Study Completion Date
    May 31, 2019 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    University of Aarhus

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    The proposed project aims to develop novel electrochemotherapeutic treatment of glioblastoma multiforme (GBM). Standard treatment has limited effect on survival and quality of life. Electrochemotherapy is a novel and promising treatment, which has demonstrated convincing results in the treatment of various types of carcinoma. The treatment is based on a combination of electrical current stimulation of tumor cells and simultaneous administration of chemotherapeutic drugs. Electrochemotherapy works by inducing an electrical current between implanted electrodes in the tumor tissue, causing electroporation of the cancer cell membranes, and thereby increasing the cellular permeability and drug uptake. Electrochemotherapy has proven to be an efficient way of considerably increasing the potency of the chemotherapeutic drug bleomycin in malignant cells in skin tumors and carcinoma metastases, and thereby increasing cytotoxicity of the drug locally in the tumor tissue. This allows for treatment with lower doses of chemotherapeutic drugs and more defined, local area of effect, thus decreasing systemic effects. The investigators propose to use a novel non-invasive and safe technique called focused transcranial magnetic stimulation (focused TMS) to induce electrical current in the tumor tissue. TMS is a safe and widely implemented technology used to treat multiple neurological diseases such as pain, depression and stroke. Studies have shown that effective electroporation of cell membranes can be obtained using induction of electromagnetic fields in a cell suspension, and new focused TMS further enables focused treatment of selected brain regions without surgical intervention and, thereby focusing chemotherapeutic treatment to pathological tissue and avoiding surgery related brain tissue damage. Additionally, TMS transiently increases blood-brain barrier permeability, theoretically allowing increased uptake of chemotherapeutic drugs in the target area. This addresses a significant challenge in the treatment of brain cancer, as most cytotoxic drugs have fairly limited ability to pass the blood brain barrier. The intention of this research project is to investigate the therapeutic potential of focused TMS as an alternative non-invasive source of current induction and thereby means to treat several types of brain cancer with electrochemotherapy.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Glioblastoma

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    TMS electrochemotherapy
    Arm Type
    Experimental
    Arm Description
    Combined TMS (transcranial magnetic stimulation) and Temozolomide chemotherapy.
    Intervention Type
    Device
    Intervention Name(s)
    TMS
    Other Intervention Name(s)
    Transcranial Magnetic Stimulation
    Intervention Description
    Pulsed non-invasive brain stimulation using electromagnets
    Primary Outcome Measure Information:
    Title
    Time to death
    Description
    Time from onset primary diagnosis until death
    Time Frame
    3 years
    Secondary Outcome Measure Information:
    Title
    Time to progression
    Description
    Time from diagnosis until radiological tumor progression
    Time Frame
    3 years
    Title
    Quality of Life
    Time Frame
    3 years

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Newly diagnosed and histologically confirmed glioblastoma multiform MGMT gene methylation If age < 70, eligibility to comply with the Stupp radio chemotherapy regimen If age > 70, eligibility for stand alone chemotherapeutic treatment Ability to comply with the proposed TMS treatment Use of validated anti-conception for fertile female participants in concordance with guidelines provided by the Danish Health and Medicines Authority Exclusion Criteria: Pregnancy or nursing Other conditions that may contraindicate the use of transcranial magnetic stimulation Implanted pacemaker or metal contraindicating MRI-scan
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Anders R Korshøj, MD
    Organizational Affiliation
    Aarhus University Hospital, Department of Neurosurgery
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    TMS Electrochemotherapy for Glioblastoma Multiforme

    We'll reach out to this number within 24 hrs